Two IDH inhibitors, ivosedinib (an IDH1 inhibitor) and enasedinib (an IDH2 inhibitor) demonstrated efficacy against gliomas, cholangiocarcinomas, and AML in clinical trials [167,168,169,170]. This evidence concerns the gene IDH1 and acute myeloid leukemia.